Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus S1 in advanced gastric cancer
NCT03271073Phase 2Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Feb 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in gastric cancer (GC), sponsored by Beijing Friendship Hospital. Primary endpoint: Progression-free survival at 1 year. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03271073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03271073.